Conference Proceedings

A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.

Gary D Steinberg, Joan Palou-Redorta, Juergen E Gschwend, Ben Tran, Yohann Loriot, Siamak Daneshmand, Morgan Roupret, Ademi E Santiago-Walker, Julie C Switzky, Christopher Major, Mahadi Baig, Qi Xia, James WF Catto

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2020


TPS603 Background: ERDA, an oral pan-FGFR inhibitor, is approved by the US FDA for metastatic urothelial carcinoma (mUC) with susceptible FGFR3 or FGFR2 gene alterations and progressed on/ or after at least 1 line of prior platinum-containing chemotherapy (PCC) including within 12 months of neoadjuvant/adjuvant PCC.1 Around 40% of patients with bladder cancer present with HR-NMIBC. First-line BCG therapy fails in 30-40% of patients and subsequent treatment options are limited. This study is designed to evaluate recurrence-free survival (RFS) following treatment with ERDA vs IC in patients with FGFR positive HR-NMIBC who recurred after BCG therapy. Methods: This is an open-label, multicenter..

View full abstract


Citation metrics